Bet on a reduced-risk, global innovator in drug delivery platforms with Lexaria
There are plenty of biotechnology businesses that focus entirely on novel drugs. But what about the delivery of those drugs – is there money to be made in this growing field?
The answer is definitely yes, and Lexaria Bioscience Corp. (LEXX) is proving it. Believe it or not, the company posted revenue growth of more than 150% from 2020 to 2021.
That figure is impressive, but really it’s only the beginning of Lexaria’s journey to potentially massive profitability. After all, a cumulative market value of over $245 billion has been identified for Lexaria’s drug delivery platform, known as DehydraTECH.
These markets range from CBD to anti-virals, epilepsy, NSAIDs, nicotine replacement and more. And as we’ll discuss in a moment, LEXX stock achieved a crucial milestone in 2021 which sets it up for bigger and better things in 2022.
A Closer Look at LEXX Stock
So, I won’t keep you in suspense any longer. I milestone moment occurred when Lexaria Bioscience Corp. was uplisted to Nasdaq Capital Markets with US$11 million raised at $5.25 in January 2021, as well as $4 million raised at $6.58 in July 2021.
Not just any company and stock gets a NASDAQ uplisting, so clearly Lexaria is a company to watch. Plus, now you could have an opportunity to grab some shares of LEXX stock at a reduced price point.
As I’m writing this, LEXX stock happens to be trading at the bottom of its range. In fact, the stock has moved reliably from $5 to roughly $10 since its NASDAQ uplisting.
A great strategy for investors is to take advantage of LEXX stock anywhere near $5 and if it’s below that price, you can double down as there’s a high probability of LEXX returning to $10 and then scaling higher.
A Better Delivery Methodology
I already touched upon Lexaria’s drug delivery platform, DehydraTECH, but you really need to appreciate the innovation that’s at work here.
DehydraTECH works symbiotically with existing physiological systems to enable improved and more rapid absorption into the bloodstream and brain tissues.
It’s designed specifically for formulating and delivering fat-soluble drugs and active ingredients. DehydraTECH is protected by a robust suite of patents-pending or patents granted around the world covering its use with a broad range of bioactive molecules, including nicotine, common NSAID pain-relievers, and much more.
So basically, Lexaria doesn’t have to come up with new drugs and get them approved by strict regulators. Rather, Lexaria’s technology is best thought of as an additional layer that companies offering consumer supplements, prescription and non-prescription based drugs, and nicotine products can utilize to improve the effectiveness of their existing or planned new products.
And here’s some good news: Lexaria Bioscience Corp. has no plans to create and sell any Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its advanced technology to other companies around the world to offer consumers the best performance possible across an array of product formats.
The Proof’s in the Data
So, here’s an example of how much more effective drug deliver can be with DehydraTECH.
A 2018 double-blind European human clinical study, in which 90 mg CBD doses were delivered with DehydraTECH vs. positive control oral capsules, showed that 317% more CBD was delivered at 30 minutes or less, and with lower blood pressure shown vs. the baseline result.
DehydraTECH’s practical applications are seemingly endless. In fact, Lexaria just announced a significant new study to expand its hypertension clinical program and provided updates on three ongoing human clinical studies evaluating its proprietary DehydraTECH-CBD for potentially treating hypertension and heart disease.
On top of all that, Chris Bunka, CEO of Lexaria Bioscience Corp., revealed even more potential applications for this innovative technology in 2022.
“Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking”, Bunka explained.
“We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease and diabetes,” the CEO added.
The Bottom Line
LEXX stock definitely deserves to be trading on the well-regarded NASDAQ Exchange.
The company is proving itself as a true trailblazer in drug delivery technology. DehydraTECH’s scientific applications will continue to expand in the coming year and beyond.
With that in mind, Lexaria Bioscience Corp. should be on your medical-niche stock shopping list, if it’s not already.
